310 related articles for article (PubMed ID: 31228095)
1. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.
Jiang W; Withers B; Sutrave G; Clancy LE; Yong MI; Blyth E
Curr Hematol Malig Rep; 2019 Aug; 14(4):247-260. PubMed ID: 31228095
[TBL] [Abstract][Full Text] [Related]
2. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
3. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
4. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
5. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
[TBL] [Abstract][Full Text] [Related]
7. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Vera JF; Rooney CM; Leen AM
J Vis Exp; 2011 May; (51):. PubMed ID: 21654628
[TBL] [Abstract][Full Text] [Related]
8. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
Sili U; Leen AM; Vera JF; Gee AP; Huls H; Heslop HE; Bollard CM; Rooney CM
Cytotherapy; 2012 Jan; 14(1):7-11. PubMed ID: 22172091
[TBL] [Abstract][Full Text] [Related]
9. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
10. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
Zandvliet ML; van Liempt E; Jedema I; Kruithof S; Kester MG; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2011 Apr; 34(3):307-19. PubMed ID: 21389867
[TBL] [Abstract][Full Text] [Related]
12. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.
Khanna N; Stuehler C; Conrad B; Lurati S; Krappmann S; Einsele H; Berges C; Topp MS
Blood; 2011 Jul; 118(4):1121-31. PubMed ID: 21642594
[TBL] [Abstract][Full Text] [Related]
13. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
14. Cellular immune therapy for viral infections in transplant patients.
Khanna R; Smith C
Indian J Med Res; 2013 Nov; 138(5):796-807. PubMed ID: 24434332
[TBL] [Abstract][Full Text] [Related]
15. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.
Baugh KA; Tzannou I; Leen AM
Curr Opin Infect Dis; 2018 Aug; 31(4):292-300. PubMed ID: 29750672
[TBL] [Abstract][Full Text] [Related]
16. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with virus-specific T cells.
Fuji S; Kapp M; Grigoleit GU; Einsele H
Best Pract Res Clin Haematol; 2011 Sep; 24(3):413-9. PubMed ID: 21925094
[TBL] [Abstract][Full Text] [Related]
18. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
Gerdemann U; Keirnan JM; Katari UL; Yanagisawa R; Christin AS; Huye LE; Perna SK; Ennamuri S; Gottschalk S; Brenner MK; Heslop HE; Rooney CM; Leen AM
Mol Ther; 2012 Aug; 20(8):1622-32. PubMed ID: 22801446
[TBL] [Abstract][Full Text] [Related]
19. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation.
Kállay K; Kassa C; Réti M; Karászi É; Sinkó J; Goda V; Stréhn A; Csordás K; Horváth O; Szederjesi A; Tasnády S; Hardi A; Kriván G
J Immunother; 2018 Apr; 41(3):158-163. PubMed ID: 29239916
[TBL] [Abstract][Full Text] [Related]
20. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
